Nectar Lifescience Ltd (NECLIFE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 216478,
    "name": "Nectar Lifesci.",
    "stock_name": "Nectar Lifesci.",
    "full_name": "Nectar Lifescience Ltd",
    "name_url": "stocks-analysis/nectar-lifesci",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "13.92",
    "chg": -0.01,
    "chgp": "-0.07%",
    "dir": -1,
    "prev_price": "13.93",
    "mcapval": "270.41 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532649,
    "symbol": "NECLIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE023H01027",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "3.38 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/nectar-lifesci-216478-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nectar Lifescience Sees Exceptional Trading Volume Amidst Market Activity",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-surges-on-exceptional-volume-amid-strong-sell-rating-3746034",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NectarLifescien_most_active_equities_by_volume_3746034.png",
        "date": "2025-12-04 10:00:12",
        "description": "Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded one of the highest trading volumes on 4 December 2025, with over 1.91 crore shares exchanging hands. The stock demonstrated notable price movement, opening sharply higher and outperforming its sector peers, signalling heightened market interest and active participation despite a decline in delivery volumes."
      },
      {
        "title": "Nectar Lifesci. Sees Revision in Market Evaluation Amidst Challenging Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifesci-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3741251",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NectarLifesci_mojoScore_3741251.png",
        "date": "2025-12-02 10:09:20",
        "description": "Nectar Lifesci., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s operational performance, valuation risks, and market behaviour, signalling a cautious stance for investors navigating this volatile stock."
      },
      {
        "title": "Nectar Lifescience Surges with Unprecedented Buying Interest, Hits Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-surges-to-upper-circuit-on-unprecedented-buying-interest-3735716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_only_buyers_3735716.png",
        "date": "2025-11-28 13:35:13",
        "description": "Nectar Lifescience Ltd witnessed extraordinary buying momentum on 28 Nov 2025, with the stock hitting the upper circuit limit and registering a near 20% gain in a single trading session. The surge was marked by an absence of sellers, creating a unique scenario where only buy orders were queued, signalling intense demand and potential for a multi-day circuit scenario."
      },
      {
        "title": "Nectar Lifescience Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-surges-176-to-hit-upper-circuit-amid-robust-buying-pressure-3735290",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_stocks_hitting_upper_circuit_3735290.png",
        "date": "2025-11-28 10:00:14",
        "description": "Nectar Lifescience Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit with a remarkable 17.58% gain. The stock demonstrated robust buying interest, outpacing its sector and broader market indices, while trading volumes and turnover reflected heightened investor participation."
      },
      {
        "title": "Nectar Lifescience Sees Exceptional Trading Volume Amidst Market Activity",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-surges-on-exceptional-volume-amid-strong-market-activity-3735248",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_most_active_equities_by_volume_3735248.png",
        "date": "2025-11-28 10:00:10",
        "description": "Nectar Lifescience Ltd has emerged as one of the most actively traded stocks on 28 November 2025, registering a significant surge in trading volume and price movement. The pharmaceutical and biotechnology company’s shares witnessed a notable uptick in investor participation, reflecting heightened market interest and dynamic trading patterns."
      },
      {
        "title": "Why is Nectar Lifesci. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-nectar-lifesci-fallingrising-3721940",
        "imagepath": "",
        "date": "2025-11-22 00:41:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Short-Term Gains</strong></p>\n<p>The stock has demonstrated a notable recovery in the past month, delivering an 11.19% return compared to the Sensex’s modest 0.95% gain over the same period. This recent momentum is further underscored by the stock’s consecutive gains over the last three trading sessions, during which it has appreciated by 7.64%. On 21-Nov, the share price increased by ₹0.66, outperforming its sector by 5.19%, signalling renewed investor interest and positive sentiment in the near term.</p>\n<p>Technical indicators provide additional context for this rise. The current price stands above the 5-day, 20-day, and 50-day moving averages, suggesting short- to medium-term bullishness. However, it remains below the 100-day and 200-day moving averages, indicat..."
      },
      {
        "title": "Why is Nectar Lifesci. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-nectar-lifesci-fallingrising-3712904",
        "imagepath": "",
        "date": "2025-11-18 22:05:41",
        "description": "As of 18-Nov, Nectar Lifescience Ltd is experiencing a decline in its stock price, currently at Rs 13.75, which represents a decrease of 0.89 or 6.08%. The stock has been underperforming significantly, with a consecutive fall over the last three days resulting in a total drop of 13.63%. It is currently trading lower than all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, the stock is close to its 52-week low, just 3.64% away from Rs 13.25. The delivery volume has also decreased by 22.67% compared to the 5-day average, indicating falling investor participation. The stock's year-to-date performance shows a staggering decline of 64.74%, contrasting sharply with the Sensex's gain of 8.36%.\n\nIn the broader market context, Nectar Lifescience's short-term performance has been notably poor compared to the benchmark, as it has declined by 5.43% over the past we..."
      },
      {
        "title": "Nectar Lifescience Q2 FY26: Steep Losses Deepen as Operations Collapse",
        "link": "https://www.marketsmojo.com/news/result-analysis/nectar-lifescience-q2-fy26-steep-losses-deepen-as-operations-collapse-3718720",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_quaterlyResult_3718720.png",
        "date": "2025-11-18 16:20:02",
        "description": "Nectar Lifescience Ltd., a specialised cephalosporins manufacturer, reported a consolidated net loss of ₹176.01 crores for Q2 FY26, marking a catastrophic deterioration from the ₹5.60 crore profit posted in the corresponding quarter last year. The micro-cap pharmaceutical company's operational collapse has accelerated, with revenues plummeting 98.78% quarter-on-quarter to just ₹5.71 crores, signalling severe distress in its core business operations."
      },
      {
        "title": "Nectar Lifescience Faces Financial Challenges Amidst Mixed Operational Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifesciences-financial-trend-improves-from-negative-to-flat-despite-declining-sales-3709568",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NectarLifescien_fintrenddot_3709568.png",
        "date": "2025-11-18 08:00:14",
        "description": "Nectar Lifescience has reported a challenging quarter with a significant decline in financial performance, including a drastic drop in net sales and a negative Profit After Tax. Despite achieving a high Return on Capital Employed and strong receivables management, the company faces increased leverage and struggles to regain market confidence."
      }
    ],
    "total": 552,
    "sid": "216478",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/nectar-lifescience-216478"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011",
      "datetime": "30-Jan-2026",
      "details": "The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(3) and 4(c) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "29-Jan-2026",
      "details": "Please find attached herewith copy of newspaper publication about dispatch/ mailing of Postal Ballot Notice",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
      "datetime": "28-Jan-2026",
      "details": "Please find enclosed the Postal Ballot Notice together with the Explanatory Statement thereto seeking approval of the Members for Appointment of Mr. Sushil Kapoor as a Director of the Company liable to retire by rotation as well as Wholetime Director designated as Director (Finance) and to adopt the new set of memorandum of association with amended object clause of the Company and as set out in the said Notice. The Notice is also available on the website of the Company i.e. www.neclife.com/about-3-9 and website of KFin Technologies Limited at https://evoting.kfintech.com. Members whose names appeared in the Register of Members/ List of Beneficial Owners as on the cut-off date i.e. Friday January 23 2026 are eligible for the purpose of remote e-voting. The remote e-voting period shall commence on Friday January 30 2026 09:00 A.M (IST) and will end on Saturday February 28 2026 05:00 P.M. (IST). The results of the Postal Ballot will be announced on or before March 02 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Nectar Lifescience Ltd has declared <strong>5%</strong> dividend, ex-date: 11 Sep 20",
          "dt": "2020-09-11",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Nectar Lifescience Ltd has announced <strong>1:10</strong> stock split, ex-date: 12 Nov 08",
          "dt": "2008-11-12",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Nectar Lifescience Sees Exceptional Trading Volume Amidst Market Activity

2025-12-04 10:00:12

Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded one of the highest trading volumes on 4 December 2025, with over 1.91 crore shares exchanging hands. The stock demonstrated notable price movement, opening sharply higher and outperforming its sector peers, signalling heightened market interest and active participation despite a decline in delivery volumes.

Nectar Lifesci. Sees Revision in Market Evaluation Amidst Challenging Financials

2025-12-02 10:09:20

Nectar Lifesci., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s operational performance, valuation risks, and market behaviour, signalling a cautious stance for investors navigating this volatile stock.

Nectar Lifescience Surges with Unprecedented Buying Interest, Hits Upper Circuit

2025-11-28 13:35:13

Nectar Lifescience Ltd witnessed extraordinary buying momentum on 28 Nov 2025, with the stock hitting the upper circuit limit and registering a near 20% gain in a single trading session. The surge was marked by an absence of sellers, creating a unique scenario where only buy orders were queued, signalling intense demand and potential for a multi-day circuit scenario.

Nectar Lifescience Hits Upper Circuit Amid Strong Buying Pressure

2025-11-28 10:00:14

Nectar Lifescience Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit with a remarkable 17.58% gain. The stock demonstrated robust buying interest, outpacing its sector and broader market indices, while trading volumes and turnover reflected heightened investor participation.

Nectar Lifescience Sees Exceptional Trading Volume Amidst Market Activity

2025-11-28 10:00:10

Nectar Lifescience Ltd has emerged as one of the most actively traded stocks on 28 November 2025, registering a significant surge in trading volume and price movement. The pharmaceutical and biotechnology company’s shares witnessed a notable uptick in investor participation, reflecting heightened market interest and dynamic trading patterns.

Why is Nectar Lifesci. falling/rising?

2025-11-22 00:41:11

Recent Price Movement and Short-Term Gains The stock has demonstrated a notable recovery in the past month, delivering an 11.19% return compared to the Sensex’s modest 0.95% gain over the same period. This recent momentum is further underscored by the stock’s consecutive gains over the last three trading sessions, during which it has appreciated by 7.64%. On 21-Nov, the share price increased by ₹0.66, outperforming its sector by 5.19%, signalling renewed investor interest and positive sentiment in the near term. Technical indicators provide additional context for this rise. The current price stands above the 5-day, 20-day, and 50-day moving averages, suggesting short- to medium-term bullishness. However, it remains below the 100-day and 200-day moving averages, indicat...

Why is Nectar Lifesci. falling/rising?

2025-11-18 22:05:41

As of 18-Nov, Nectar Lifescience Ltd is experiencing a decline in its stock price, currently at Rs 13.75, which represents a decrease of 0.89 or 6.08%. The stock has been underperforming significantly, with a consecutive fall over the last three days resulting in a total drop of 13.63%. It is currently trading lower than all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, the stock is close to its 52-week low, just 3.64% away from Rs 13.25. The delivery volume has also decreased by 22.67% compared to the 5-day average, indicating falling investor participation. The stock's year-to-date performance shows a staggering decline of 64.74%, contrasting sharply with the Sensex's gain of 8.36%. In the broader market context, Nectar Lifescience's short-term performance has been notably poor compared to the benchmark, as it has declined by 5.43% over the past we...

Nectar Lifescience Q2 FY26: Steep Losses Deepen as Operations Collapse

2025-11-18 16:20:02

Nectar Lifescience Ltd., a specialised cephalosporins manufacturer, reported a consolidated net loss of ₹176.01 crores for Q2 FY26, marking a catastrophic deterioration from the ₹5.60 crore profit posted in the corresponding quarter last year. The micro-cap pharmaceutical company's operational collapse has accelerated, with revenues plummeting 98.78% quarter-on-quarter to just ₹5.71 crores, signalling severe distress in its core business operations.

Nectar Lifescience Faces Financial Challenges Amidst Mixed Operational Performance Metrics

2025-11-18 08:00:14

Nectar Lifescience has reported a challenging quarter with a significant decline in financial performance, including a drastic drop in net sales and a negative Profit After Tax. Despite achieving a high Return on Capital Employed and strong receivables management, the company faces increased leverage and struggles to regain market confidence.

View All News

Announcement

Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011

30-Jan-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(3) and 4(c) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for

Announcement under Regulation 30 (LODR)-Newspaper Publication

29-Jan-2026 | Source : BSE

Please find attached herewith copy of newspaper publication about dispatch/ mailing of Postal Ballot Notice

Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

28-Jan-2026 | Source : BSE

Please find enclosed the Postal Ballot Notice together with the Explanatory Statement thereto seeking approval of the Members for Appointment of Mr. Sushil Kapoor as a Director of the Company liable to retire by rotation as well as Wholetime Director designated as Director (Finance) and to adopt the new set of memorandum of association with amended object clause of the Company and as set out in the said Notice. The Notice is also available on the website of the Company i.e. www.neclife.com/about-3-9 and website of KFin Technologies Limited at https://evoting.kfintech.com. Members whose names appeared in the Register of Members/ List of Beneficial Owners as on the cut-off date i.e. Friday January 23 2026 are eligible for the purpose of remote e-voting. The remote e-voting period shall commence on Friday January 30 2026 09:00 A.M (IST) and will end on Saturday February 28 2026 05:00 P.M. (IST). The results of the Postal Ballot will be announced on or before March 02 2026.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Nectar Lifescience Ltd has declared 5% dividend, ex-date: 11 Sep 20

SPLITS

Nectar Lifescience Ltd has announced 1:10 stock split, ex-date: 12 Nov 08

BONUS

No Bonus history available

RIGHTS

No Rights history available

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."